Patent ID: 9157076
Filing Date: 2015-10-13
Classification: A61K,A61P,C07K,C12N,C12Y

Abstract:
1. A method for treating a condition comprising administering to a subject in need thereof a therapeutic composition, comprising a pharmaceutically-acceptable carrier and an isolated glycyl-tRNA synthetase (GRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:1, (b) a fragment of (a) comprising at least 600 contiguous amino acids of SEQ ID NO:1, and (c) a variant of (a) having at least 95% identity to SEQ ID NO:1, where the GRS polypeptide has cell signaling activity and is at least about 90% pure, where the composition is sterile and pyrogen-free, and where the condition is selected from the group consisting of inflammatory diseases, autoimmune diseases, neoplastic diseases, metabolic diseases, neurological diseases, infections, cardiovascular diseases, and diseases associated with abnormal angiogenesis.